跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/EUCTR2021-000211-23-ES
EUCTR2021-000211-23-ES进行中（未招募）1 期

A Phase 3, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Mitapivat in Subjects With Non Transfusion-Dependent Alpha- or Beta-Thalassemia (ENERGIZE)

Agios Pharmaceuticals, Inc.0 个研究点目标入组 171 人开始时间: 2021年6月11日最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
适应症

试验速览

阶段
1 期
状态
进行中（未招募）
入组人数
171
研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • •Subjects are eligible to be included in the study only if all the following criteria apply:
  • •1. =18 years of age at the time of providing informed consent.
  • •2. Documented diagnosis of thalassemia (ß-thalassemia with or without a-globin gene
  • •mutations, HbE/ß-thalassemia, or a-thalassemia/HbH disease) based on Hb electrophoresis, Hb high-performance liquid chromatography, and/or DNA analysis from the subject’s medical record. If this information is not available from the subject’s
  • •medical record, the test(s) can be performed by a local laboratory during the Screening
  • •Period. If a local laboratory is unable to perform the test(s), results from the comprehensive a- and ß-globin genotyping performed by the study central laboratory can be used.
  • •3. Hb concentration =10.0 g/dL, based on an average of at least 2 Hb concentration
  • •measurements (separated by =7 days) collected during the Screening Period.
  • •4. Non–transfusion dependent, defined as =5 RBC units during the 24-week period before randomization, and no RBC transfusions =8 weeks before providing informed consent or during the Screening Period.
  • •5. If taking hydroxyurea, the hydroxyurea dose must be stable for =16 weeks before
  • •randomization.
  • •6. Women of childbearing potential (WOCBP) and men with partners who are WOCBP
  • •must be abstinent of sexual activities that may result in pregnancy as part of their usual lifestyle or agree to use 2 forms of contraception, 1 of which must be considered highly effective, from the time of providing informed consent, throughout the study, and for 28 days after the last dose of study drug for women and 90 days after the last dose of study drug for men. The second form of contraception can be an acceptable barrier method.
  • •7. Written informed consent before any study-related procedures are conducted and willing to comply with all study procedures for the duration of the study.
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1.2 Adults (18-64 years) yes
  • •F.1.2.1 Number of subjects for this age range 167
  • •F.1.3 Elderly (>=65 years) yes
  • •F.1.3.1 Number of subjects for this age range 4

排除标准

  • •Subjects are excluded from the study if any of the following criteria apply:
  • •1. Pregnant or breastfeeding.
  • •2. Documented history of homozygous or heterozygous HbS or HbC.
  • •3. Prior exposure to gene therapy or prior bone marrow or stem cell transplantation.
  • •4. Currently receiving treatment with luspatercept; the last dose must have been
  • •administered =12 weeks before screening.
  • •5. Currently receiving treatment with hematopoietic stimulating agents; the last dose must have been administered =12 weeks before screening.
  • •6. History of any malignancy, except for nonmelanomatous skin cancer in situ, cervical
  • •carcinoma in situ, or breast carcinoma in situ. Subjects must not have active disease or
  • •received anticancer treatment =5 years before providing informed consent.
  • •7. History of active and/or uncontrolled cardiac or pulmonary disease =6 months before providing informed consent, including but not limited to:
  • •a. New York Heart Association Class III or IV heart failure or clinically significant
  • •dysrhythmia
  • •b. Myocardial infarction or unstable angina pectoris; hemorrhagic, embolic, or
  • •thrombotic stroke; deep venous thrombosis; or pulmonary or arterial embolism
  • •c. Heart rate–corrected QT interval using Fridericia’s method =450 milliseconds, except
  • •for right or left bundle branch block
  • •d. Severe pulmonary fibrosis as defined by severe hypoxia, evidence of right-sided heart failure, and radiographic pulmonary fibrosis >50%
  • •e. Severe pulmonary hypertension as defined by severe symptoms associated with
  • •hypoxia, right-sided heart failure, and oxygen indicated
  • •8. Hepatobiliary disorders, including but not limited to:
  • •a. Liver disease with histopathological evidence of cirrhosis or severe fibrosis
  • •b. Clinically symptomatic cholelithiasis or cholecystitis (prior cholecystectomy is not
  • •exclusionary)
  • •c. History of drug-induced cholestatic hepatitis
  • •d. Aspartate aminotransferase (AST) >2.5 × upper limit of normal (ULN); unless due to
  • •hemolysis and hepatic iron deposition) and alanine aminotransferase (ALT) >2.5 ×
  • •ULN (unless due to hepatic iron deposition)
  • •9. Estimated glomerular filtration rate <45 mL/min/1.73 m2 by Chronic Kidney Disease
  • •Epidemiology Collaboration creatinine equation.
  • •10. Nonfasting triglycerides >440 mg/dL (5 mmol/L).
  • •11. Active infection requiring systemic antimicrobial therapy at the time of providing
  • •informed consent. If antimicrobial therapy is required during the Screening Period,
  • •screening procedures should not be performed while antimicrobial therapy is being
  • •administered, and the last dose of antimicrobial therapy must be administered =7 days
  • •before randomization.
  • •12. Positive test for hepatitis C virus (HCV) antibody (Ab) with evidence of active HCV
  • •infection, or positive test for hepatitis B surface antigen (HBsAg).
  • •13. Positive test for HIV-1 Ab or HIV-2 Ab.
  • •14. History of major surgery (including splenectomy) =16 weeks before providing informed consent and/or a major surgical procedure planned during the study.
  • •15. Current enrollment or past participation (=12 weeks before administration of the first dose of study drug or a time frame equivalent to 5 half-lives of the investigational study drug, whichever is longer) in any other clinical study involving an investigational
  • •treatment or device.
  • •16. Receiving strong CYP3A4/5 inhibitors that have not been stopped for =5 days or a time frame equivalent to 5 half-lives (whichever is longer), or strong CYP3A4 inducers that have not been stopped for =4 weeks or a time frame equivalen

研究者

相似试验

进行中（未招募）
1 期
A study to Evaluate the Efficacy and Safety of Mitapivat in Subjects With Transfusion-Dependent Alpha- or Beta-Thalassemia (ENERGIZE-T)
EUCTR2021-000212-34-NLAgios Pharmaceuticals, Inc.240
尚未招募
3 期
A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Transfusion-Dependent Alpha- or Beta-Thalassemia (a- or ß-TDT) (ENERGIZE-T).a- or ß-Transfusion Dependent Thalassemia. Transfusion dependent is defined as 6 to 20 RBC units transfused and a =6-weektransfusion-free period during the 24-week period before randomization.Thalassemia beta-Thalassemia alpha- Thalassemia Anemia, Hemolytic, Congenital Anemia, Hemolytic Anemia Hematologic Diseases
LBCTR2022014845Agios Pharmaceuticals, Inc.240
进行中（未招募）
1 期
A study to Evaluate the Efficacy and Safety of Mitapivat in Subjects With Non Transfusion-Dependent Alpha- or Beta-Thalassemia (ENERGIZE)
CTIS2024-512745-16-00Agios Pharmaceuticals Inc.105
招募中
3 期
A Phase 3, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Mitapivat in Subjects With Transfusion-Dependent Alpha- or Beta-Thalassemia (ENERGIZE-T)&alfa- or &beta- transfusion-dependent thalassemia10038158
NL-OMON56084Agios Pharmaceuticals, Inc.21
进行中（未招募）
1 期
A study to Evaluate the Efficacy and Safety of Mitapivat in Subjects With Transfusion-Dependent Alpha- or Beta-Thalassemia (ENERGIZE-T)
CTIS2024-512747-23-00Agios Pharmaceuticals Inc.171